We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


NEC and SomaLogic Enter Agreement to Prepare for Delivery of Novel Forms of Health Information via Cloud Services

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NEC and SomaLogic Enter Agreement to Prepare for Delivery of Novel Forms of Health Information via Cloud Services"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
NEC Corporation (NEC) and privately held SomaLogic, Inc. has announced that they have signed an agreement to explore aptamer (*1) related businesses in the life sciences and healthcare markets. In addition, NEC announced that it has made an equity investment in SomaLogic in support of a long-term strategic relationship between the two companies.

The agreement establishes a framework for the two companies to develop and implement applications within NEC’s cloud-based services platform to enhance SomaLogic’s products for life sciences research and diagnostics. Customers will include pharmaceutical companies, research laboratories, and practicing physicians, with the eventual goal of expanding into personal healthcare services.

“NEC is pleased to work with one of the most exciting companies emerging in the field of molecular diagnostics,” said Tadashi Higashino, Senior Vice President, NEC. “We believe that both companies can leverage their unique experiences and integrate them to provide for better healthcare, and thus enhance people’s lives, worldwide.”

“This agreement gives us a firm basis on which to create new possibilities for the future,” said Larry Gold, SomaLogic’s Founder and CEO. “We are delighted with NEC’s foresight, and we look forward to working with our NEC colleagues to find efficient and effective ways to optimize the research and clinical impact of our work.”